202 related articles for article (PubMed ID: 10817741)
1. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
[TBL] [Abstract][Full Text] [Related]
3. Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.
Borg-von Zepelin M; Zaschke K; Gross U; Monod M; Müller FM
Chemotherapy; 2002 Jul; 48(3):148-53. PubMed ID: 12138332
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
6. [The future of antifungal agents. Non azole antifungal agents].
Maesaki S; Hossain MA; Sasaki E; Hashiguchi K; Higashiyama Y; Yoshitsugu Y; Tomono K; Tashiro T; Kohno S
Nihon Ishinkin Gakkai Zasshi; 1999; 40(3):157-61. PubMed ID: 10423510
[TBL] [Abstract][Full Text] [Related]
7. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
Ikeda F
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
Mikamo H; Sato Y; Tamaya T
J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
[TBL] [Abstract][Full Text] [Related]
9. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
10. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
11. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.
Wiederhold NP; Lewis JS
Expert Opin Pharmacother; 2007 Jun; 8(8):1155-66. PubMed ID: 17516879
[TBL] [Abstract][Full Text] [Related]
12. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
13. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Hope WW; Drusano GL; Moore CB; Sharp A; Louie A; Walsh TJ; Denning DW; Warn PA
Antimicrob Agents Chemother; 2007 Jan; 51(1):285-95. PubMed ID: 17088486
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
15. [Antifungal activity and clinical efficacy of micafungin (funguard)].
Ikeda F
Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):217-22. PubMed ID: 16282962
[TBL] [Abstract][Full Text] [Related]
16. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
17. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.
Maesaki S; Marichal P; Hossain MA; Sanglard D; Vanden Bossche H; Kohno S
J Antimicrob Chemother; 1998 Dec; 42(6):747-53. PubMed ID: 10052898
[TBL] [Abstract][Full Text] [Related]
18. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
19. Micafungin activity against Candida albicans with diverse azole resistance phenotypes.
Richards TS; Oliver BG; White TC
J Antimicrob Chemother; 2008 Aug; 62(2):349-55. PubMed ID: 18436555
[TBL] [Abstract][Full Text] [Related]
20. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.
Warn PA; Sharp A; Morrissey G; Denning DW
J Antimicrob Chemother; 2002 Dec; 50(6):1071-4. PubMed ID: 12461036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
